A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9

https://doi.org/10.1016/j.ymgme.2009.09.012Get rights and content

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the extracellular domain of the low density lipoprotein receptor (LDLR) at the cell surface, and disrupts the normal recycling of the LDLR. However, the exact mechanism by which the LDLR is re-routed for lysosomal degradation remains to be determined. To clarify the role of the cytoplasmic domain of the LDLR for re-routing to the lysosomes, we have studied the ability of PCSK9 to degrade a chimeric receptor which contains the extracellular and transmembrane domains of the LDLR and the cytoplasmic domain of the transferrin receptor. These studies were performed in CHO T-REx cells stably transfected with a plasmid encoding the chimeric receptor and a novel assay was developed to study the effect of PCSK9 on the LDLR in these cells. Localization, function and stability of the chimeric receptor were similar to that of the wild-type LDLR. The addition of purified gain-of-function mutant D374Y-PCSK9 to the culture medium of stably transfected CHO T-REx cells showed that the chimeric receptor was degraded, albeit to a lower extent than the wild-type LDLR. In addition, a mutant LDLR, which has the three lysines in the intracellular domain substituted with arginines, was also degraded by D374Y-PCSK9. Thus, the mechanism for the PCSK9-mediated degradation of the LDLR does not appear to involve an interaction between the endosomal sorting machinery and LDLR-specific motifs in the cytoplasmic domain. Moreover, ubiquitination of lysines in the cytoplasmic domain does not appear to play a critical role in the PCSK9-mediated degradation of the LDLR.

Introduction

The plasma level of low density lipoprotein (LDL)1 cholesterol is regulated both by environmental and genetic factors and the LDL receptor (LDLR) plays a key role in determining plasma LDL cholesterol levels [1]. The importance of the LDLR is illustrated by the severe hypercholesterolemia in patients with familial hypercholesterolemia, who have defective LDLR due to mutations in the LDLR gene [1].

The number of LDLR is regulated both at the transcriptional level and at the post-transcriptional level. Regulation at the transcriptional level is mediated by transcription factors which bind to regulatory elements of the promoter region. Whereas, transcription factor Sp1 is constitutively expressed [2], the sterol regulatory element binding protein is activated when intracellular levels of cholesterol are low [3]. Regulation of the LDLR at the post-transcriptional level is mediated partly by factors affecting mRNA stability [4] and translation efficiency [5] and partly by post-translational degradation mediated by proprotein convertase subtilisin/kexin type 9 (PCSK9) [6], [7], [8]. Very recently myosin regulatory light chain interacting protein [9] has also been found to mediate degradation of the LDLR [10].

PCSK9 is a zymogen which undergoes autocatalytic cleavage in the endoplasmic reticulum and is secreted as a complex consisting of the cleaved prodomain non-covalently bound to the mature PCSK9 [11]. However, unlike other proprotein convertases, PCSK9 does not appear to undergo a second autocatalytic event to release an active convertase [12]. Thus, PCSK9 is found as an enzymatically inactive protein in the media of cultured cells and in human plasma.

Secreted PCSK9 is able to bind to the epidermal growth factor (EGF)-like repeat A of the LDLR at the cell surface [13], and the PCSK9:LDLR complex is internalized by endocytosis through clathrin-coated pits [7], [13]. At the acidic pH of endosomes, the affinity of PCSK9 to bind to the LDLR increases approximately 150-fold [14], [15] and bound PCSK9 somehow disrupts the normal recycling of the LDLR [6], [7], [8]. As a consequence, the LDLR with bound PCSK9 is directed to the lysosomes for degradation [13]. Thus, by binding to the LDLR at the cell surface, PCSK9 post-translationally regulates the number of cell-surface LDLR. However, the exact mechanism by which bound PCSK9 reshuttles the LDLRs to the lysosomes, remains to be determined. Mutations in the PCSK9 gene may increase or decrease the LDLR-degrading activity of the mutant PCSK9 [16], [17]. Mutations which cause autosomal dominant hypercholesterolemia or autosomal dominant hypocholesterolemia are referred to as gain-of-function or loss-of-function mutations, respectively.

Whereas, the structural requirements of the extracellular part of the LDLR for PCSK9-mediated degradation have been elegantly depicted [13], [18], the mechanism by which the LDLR is reshutteled to lysosomal degradation, is unknown. A possible mechanism of action could be that PCSK9 disrupts the normal recycling of the LDLR by affecting the interaction between the cytoplasmic domain of the LDLR and the endosomal sorting machinery. To determine the role of the cytoplasmic domain of the LDLR for PCSK9-mediated degradation, we have studied the ability of PCSK9 to degrade a chimeric receptor which contains the extracellular and transmembrane domains of the LDLR and the cytoplasmic domain of the transferrin receptor (TFRC). Thus, in the chimeric LDLR-TFRC the 50 residues of the cytoplasmic domain of the LDLR have been replaced by the 61 residues of the cytoplasmic domain of the TFRC. There are no common motifs in the cytoplasmic domains of the two receptors (Fig. 1). Moreover, the TFRC itself is not degraded by PCSK9 [6], [19].

Section snippets

Cell cultures

CHO T-REx cells (Invitrogen, Carlsbad, CA) are stably transfected with a tetracycline repressor which enables tetracycline-induced expression of genes cloned into plasmids containing the tetracycline operator 2 element. Stably transfected CHO T-REx cells were maintained in Ham’s F-12 medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, 100 μg/ml blasticidine and 100 μg/ml zeocin in a humidified atmosphere (37 °C, 5% CO2). Stably transfected

Establishing an assay to study the effect of PCSK9 on LDLR in stably transfected CHO T-REx cells

The wild-type (WT)-LDLR synthesized from the pcDNA4-LDLR plasmid in stably transfected CHO T-REx cells was found to be relatively insensitive to degradation by PCSK9 due to high expression of the pcDNA4-LDLR plasmid by the strong cytomegalovirus immediate-early promoter of the pcDNA4 vector. This is shown in Fig. 2 where CHO T-REx cells stably transfected with pcDNA4-LDLR plasmid were incubated with 0–20 μg/ml of purified D374Y-PCSK9. The gain-of-function mutant D374Y-PCSK9 was used for these

Discussion

In this report we have performed studies to determine whether the PCSK9-mediated degradation of the LDLR depends on specific residues in the cytoplasmic domain of the LDLR. A chimeric LDLR-TFRC containing the membrane-spanning and extracellular domains of the LDLR and the cytoplasmic domain of the TFRC was used for these studies. In order to be able to study PCSK9-mediated degradation of highly expressed LDLR in stably transfected cells, a novel assay was developed. We found that the chimeric

References (36)

Cited by (27)

  • PCSK9 and cancer: Rethinking the link

    2021, Biomedicine and Pharmacotherapy
  • Studies of the autoinhibitory segment comprising residues 31–60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations

    2016, Molecular Genetics and Metabolism Reports
    Citation Excerpt :

    Thus, it appears that furin-cleaved PCSK9 is not internalized by the LDLR. The explanation for the failure of WT-PCSK9 to reduce the amount of LDLR in these stably transfected CHO T-REx cells, is due to the very high expression of the LDLR in these cells [22]. To confirm that furin-cleaved PCSK9 does not disrupt the normal recycling of the LDLR, HepG2 cells were incubated with equal amounts of furin-cleaved or WT-PCSK9, and the amounts of LDLRs in cell lysates were determined by Western blot analysis.

  • The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion

    2014, Cell Metabolism
    Citation Excerpt :

    PCSK9 is a soluble protein unable to interact on its own with adaptor proteins coating the outer surface of subcellular compartments. Furthermore, the effect of PCSK9 on LDLR is independent of the LDLR intracellular domain (Holla et al., 2010). Thus, the existence of PCSK9 sorting receptors can be predicted.

  • The UPS and downs of cholesterol homeostasis

    2014, Trends in Biochemical Sciences
    Citation Excerpt :

    PCSK9-bound LDLR is then internalized via clathrin-mediated endocytosis, and directed to the lysosome where it is degraded [52]. This mode of LDLR degradation is ubiquitin-independent [52], does not require the intracellular tail of the receptor [53,54], and also applies to two receptors closely related to LDLR, very low density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2) [55]. The ubiquitin-dependent degradation of LDLR occurs through an IDOL-mediated mechanism.

  • PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment

    2013, Journal of Lipid Research
    Citation Excerpt :

    All other reagents were standard laboratory reagents. Generation of the plasmids pcDNA4-LDLR encoding the wild-type (WT) LDLR with a HA-tag (18); Δ-EGF-A-LDLR, which encodes an LDLR lacking the EGF-A repeat (19); G544V-LDLR, which encodes the Class 2a mutant LDLR caused by mutation G544V (18); Δ-β-propeller, which encodes an LDLR lacking the β-propeller (17); and E387K-LDLR, which encodes the Class 5 mutant LDLR caused by mutation E387K (19), have been previously described. The plasmid pcDNA4-LDLR was used as a template to generate the plasmid ΔOLSD-LDLR, which encodes an LDLR lacking the O-linked sugar domain (residues 693–750).

View all citing articles on Scopus
View full text